Results 51 to 60 of about 31,486 (223)

Adropin modulates pancreatic cell proliferation and glutathione levels in an animal model of type 1 diabetes mellitus

Animal Models and Experimental Medicine, EarlyView.
Adropin is related to the energy homeostasis‐associated gene. It significantly increased glutathione reductase enzyme levels in the pancreas of experimental diabetic rats. Adropin may reduce the severity of diabetes and its complications. Cell proliferation in the exocrine is reduced after the administration of adropin.
Ifrah I. Ali, Crystal D'Souza, Abderrahim Nemmar, Shreesh Ojha, Ernest A. Adeghate   +4 more
wiley   +1 more source

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 beta inhibition [PDF]

, 2006
BACKGROUND:Neonatal-onset multisystem inflammatory disease is characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation.
Adams, BS, Aksentijevich, I, Beitz, LO, Brewer, C, Butman, JA, Canna, SW, Cole, JL, Dailey, NJ, Fuhlbrigge, RC, Gardner, G, Gelabert, A, Goldbach-Mansky, R, Hannan, WP, Haverkamp, MH, Hawkins, PN, Hill, S, Hoffmann, SC, Holland, SM, Horn, W, Jarvis, JN, Jones, J, Karp, BI, Kastner, DL, Kim, HJ, Moore, TL, O'Neil, K, Paul, SM, Penzak, SR, Pham, TH, Pucino, F, Rubin, BI, Shaham, B, Snyder, C, Stein, L, Turner, ML, Vehe, RK, Warren, RW, Wesley, RA, Wiggs, E, Zalewski, C   +39 more
core  

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Tocilizumab versus anakinra in COVID-19: results from propensity score matching

Frontiers in Immunology, 2023
BackgroundTocilizumab and anakinra are anti-interleukin drugs to treat severe coronavirus disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the efficacy of tocilizumab versus anakinra to guide the choice of the therapy ...
Robin Arcani, Robin Arcani, Florian Correard, Pierre Suchon, Gilles Kaplanski, Gilles Kaplanski, Rodolphe Jean, Raphael Cauchois, Raphael Cauchois, Marine Leprince, Vincent Arcani, Julie Seguier, Benjamin De Sainte Marie, Baptiste Andre, Marie Koubi, Pascal Rossi, Stéphane Gayet, Nirvina Gobin, Victoria Garrido, Joris Weiland, Elisabeth Jouve, Anne-Laure Couderc, Anne-Laure Couderc, Patrick Villani, Patrick Villani, Aurélie Daumas, Aurélie Daumas   +26 more
doaj   +1 more source

Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition [PDF]

, 2018
Following a myocardial infarction (MI), the immune system helps to repair ischaemic damage and restore tissue integrity, but excessive inflammation has been implicated in adverse cardiac remodelling and development towards heart failure (HF).
Cleland, John G.F., Harding, Sian E., Hasham, Muneer G., Khan, Habib, Panahi, Mona, Papanikolaou, Angelos, Rosenthal, Nadia A., Sattler, Susanne, Torabi, Azam, Vazir, Ali, Zhang, Ji-Gang   +10 more
core   +2 more sources

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

Arthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian, Sophie Georgin‐Lavialle, Marcela A. Ferrada, Sinisa Savic, Matthew J. Koster, Olivier Kosmider, Thibault Comont, Mael Heilblig, Juan I. Arostegui, Annmarie Bosco, Rim Bourguiba, Katherine R. Calvo, Catherine Cargo, Chiara Cattaneo, François Chasset, Henrique Coelho, Corrado Campochiaro, Francesca Crisafulli, Stephanie Ducharme‐Benard, Raquel Faria, Franco Franceschini, Micol Frassi, Emma M. Groarke, Carmelo Gurnari, Yervand Hakobyan, Yvan Jamilloux, Ciprian Jurcut, Yohei Kirino, Austin Kulasekararaj, Hiroyoshi Kunimoto, Lauren M. Madigan, Heřman F. Mann, Chiara Marvisi, Marcin Milchert, Sara Morais, Katja Sockel, Francesco Muratore, Hideaki Nakajima, Mrinal M. Patnaik, Luísa Regadas, Marie Robin, Abraham Rutgers, Carlo Salvarani, Anthony M. Sammel, Joerg Seebach, Pierre Sujobert, Alessandro Tomelleri, Geoffrey Urbanski, Frédéric Vandergheynst, Romana Vieira, David S. Viswanatha, Ewa Więsik‐Szewczyk, Elisa Diral, Benjamin Terrier, Bhavisha A. Patel, Pierre Fenaux, Peter C. Grayson, David B. Beck, on behalf of the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases, Heřman Mann, Benjamin Terrier, François Chasset, Sophie Georgin Lavialle, Alessandro Tomelleri, Campochiaro Corrado, Carlo Salvarani, Francesca Crisafulli, Franco Franceschini, Micol Frassi, Yohei Kirino, Ewa Więsik‐Szewczyk, Marcin Milchert, Raquel Faria, Ciprian Jurcut, Joerg Seebach, Sinisa Savic, David Beck, Lauren Madigan, Matthew Koster, Patnaik Mrinal, Olivier Kosmider, Pierre Sujobert, Juan I. Arostegui, Catherine Cargo, David Viswanatha, Yervand Hagopian, Mael Heilblig, Pierre Fenaux, Thibault Comont, Bruno Alessandro, Chiara Cattaneo, Elisa Diral, Sara Morais, Austin Kulasekarara, Emma Groarke, Katherine Calvo, Patel Bhavisha, Anthony Sammel, Arsene Mekinian, Benjamin Terrier, Marie Robin, Sophie Georgin Lavialle, Katja Sockel, Yvan Jamilloux, Carmelo Gurnari, Henrique Coelho, Romana Vieira, Rim Bourguiba, Marcela Ferrada, Peter Grayson   +111 more
wiley   +1 more source

Respons Klinis Pemberian Tocilizumab Dibandingkan Anakinra dalam Tata Laksana Artritis Idiopatik Juvenil Sistemik

Sari Pediatri, 2022
Latar belakang. Artritis idiopatik juvenil (AIJ) sistemik merupakan penyakit inflamasi sistemik yang tidak hanya melibatkan sendi tetapi juga keterlibatan sistemik dan merupakan tipe terberat dari AIJ.
Edy Novery, Rizqi Amalia, Dina Muktiarti, Nia Kurniati   +3 more
doaj   +1 more source

Neonatal treatment of CINCA syndrome. [PDF]

, 2014
: Chronic Infantile Neurological Cutaneous Articular (CINCA) syndrome, also called Neonatal Onset Multisystem Inflammatory Disease (NOMID) is a chronic disease with early onset affecting mainly the central nervous system, bones and joints and may lead to
Berthet, G., Hofer, M., Mivelaz, Y., Paccaud, Y., Roth-Kleiner, M., Vaudaux, B., Von Scheven-Gête, A.   +6 more
core   +3 more sources

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies [PDF]

, 2015
The idiopathic inflammatory myopathies (IIM) constitute a heterogeneous group of chronic disorders that include dermatomyositis (DM), polymyositis (PM), sporadic inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM).
De Paepe, Boel, Zschüntzsch, Jana
core   +3 more sources